Last updated: April 26, 2026
Glipizide is a long-established, off-patent small-molecule sulfonylurea used in type 2 diabetes. The commercial supply chain is dominated by generic manufacturers, contract manufacturers, and API producers across China, India, and Europe, with multiple qualified finished-dose sources per strength and form.
Which firms supply finished-dose glipizide products?
Below are recurring branded/generic market suppliers that have published products or registrations tied to glipizide (typical tablets; immediate and extended-release products exist in the market). The practical reality for procurement is that a given strength and form (IR vs ER) can have different approved sources by geography and regulator.
United States market (typical manufacturers appearing in product supply)
Common finished-dose supply categories include:
- Generic manufacturers with ANDAs for glipizide tablets (immediate release)
- Generic manufacturers with ANDAs for glipizide extended-release tablets
- Branded supply where a particular brand persists by local market practice
Europe and Canada
European procurement usually pulls from:
- EU-authorized generics (tablets; IR and ER)
- Local distributor networks tied to MAHs (marketing authorization holders) and parallel trade
Which companies supply glipizide API?
Glipizide API supply is typically concentrated among established API producers in:
- China
- India
- Selected European API plants
API is sold as:
- Glipizide API (active ingredient for tablet formulation)
- Glipizide intermediates (less often directly procured by pharma formulators than finished API)
API supplier landscape by geography (procurement reality)
- China-based API producers: high-volume offerings, wide particle-size and polymorph control claims in CoA documentation
- India-based API producers: broad generic API portfolios for sulfonylureas and related antidiabetics
- EU-based API makers: fewer suppliers, often used when buyers require EU GMP sourcing
Which procurement routes matter most for sourcing glipizide (API or tablets)?
Procurement typically breaks into two routes:
1) Finished-dose route (tablets)
Used when:
- You need immediate commercialization readiness
- You want lower formulation and validation burden
Procurement signals:
- ANDA/MAA/marketing status by region
- GMP status, batch release documentation, and stability package completeness
- Ability to supply both IR and ER where required
2) API route (manufacture your own tablets)
Used when:
- You run in-house formulation or have a contract manufacturer
- You want to control formulation IP and supply resilience
Procurement signals:
- DMF/ASMF availability (US/Europe workflows)
- CoA, impurity profile (including specified related substances)
- Polymorph and particle-size control claims
- Supply continuity and audit outcomes
What regulatory and documentation signals should buyers screen?
API documentation (common in US/EU workflows)
- DMF / ASMF type filings for listed APIs
- GMP certificate alignment with intended markets
- CoA consistency across lots, especially for impurities and water content
Finished-dose documentation
- Market authorization status for the specific strength and IR/ER form
- Bioequivalence package references where applicable
- Stability data and shelf-life claim alignment with buyer packaging plans
Market implications: why supplier lists vary by strength and form
Glipizide is supplied as multiple dosage forms:
- Immediate-release (IR)
- Extended-release (ER)
Supply availability depends on which products are currently marketed or stocked in a buyer’s region. Even when the API is widely available, finished-dose approvals and manufacturing schedules can differ, which changes the effective supplier set for commercial procurement.
Key Takeaways
- Glipizide supply is predominantly generic and off-patent, with many qualified sources.
- Procurement must be split by finished-dose vs API and by IR vs ER, since supplier sets differ by regulatory approval and manufacturing focus.
- Buyers should screen suppliers on GMP status, DMF/ASMF documentation (for API), CoA impurity consistency, and authorization status by strength and form (for tablets).
FAQs
1) Is glipizide still under patent protection?
Glipizide is an established, off-patent molecule in most major jurisdictions; supply is driven by generics.
2) Can one API supplier cover both IR and ER tablets?
Yes, in principle; the difference is formulation and manufacturing controls. Buyers must still qualify the API and the finished-dose process for the intended product form.
3) Are there many suppliers for glipizide API?
Yes. The API market for widely used off-patent drugs typically has multiple suppliers, with concentration in Asia and a smaller set in Europe.
4) What matters most when choosing a glipizide tablet supplier?
Strength and release form (IR vs ER), regulatory authorization status in the buyer’s region, GMP compliance, and ability to deliver consistent batch release documentation.
5) What regulatory filings should buyers ask for?
For API: DMF/ASMF and GMP documentation. For finished-dose: marketing authorization and product-specific compliance packages.
References
[1] FDA. “FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] EMA. “European public assessment reports (EPAR) and product information for centrally authorized products.” European Medicines Agency. https://www.ema.europa.eu/
[3] WHO. “WHO Global Health Observatory data repository for medicines and other health topics.” World Health Organization. https://www.who.int/data/gho
